Treatment and Prognosis of Fibrolamellar Hepatocellular Carcinoma: a Systematic Review of the Recent Literature and Meta-analysis
- PMID: 36797535
- PMCID: PMC10073062
- DOI: 10.1007/s11605-023-05621-z
Treatment and Prognosis of Fibrolamellar Hepatocellular Carcinoma: a Systematic Review of the Recent Literature and Meta-analysis
Abstract
Background: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare disease and current efforts are focused on the prognosis and on the development of efficient and specific treatments. This study aimed to review the latest evidence regarding FL-HCC treatment and prognosis.
Methods: A systematic review of the literature over the past 10 years regarding FL-HCC, and meta-analysis of 1-, 3-, and 5-year overall survival (OS) comparing FL-HCC and conventional HCC were performed.
Results: Overall, 1567 articles were screened, of them 21 were selected for the systematic review, and 6 for meta-analysis. Twenty-one studies included a total of 2168 patients with FL-HCC, with a median age ranging from 11 to 56 years. The majority of patients underwent surgical resection or liver transplantation. After a median follow-up ranging from 24 to 58 months, 1-year OS was 67-100% and 5-year OS was 28-65%. A total of 743 patients with FL-HCC and 163,472 with conventional HCC were included in the meta-analysis. There was a significantly improved 1-, 3-, and 5-years OS in the FL-HCC group compared to the conventional HCC group, although high heterogeneity was found. When excluding population-based studies, and including 96 FL-HCC and 221 conventional HCC patients, the heterogeneity was low, and the meta-analysis showed a significantly longer 1-year OS in patients with FL-HCC than conventional HCC; however, there were no differences at 3- and 5-years OS.
Conclusions: Surgical resection for FL-HCC is currently the only curative treatment available. FL-HCC is plagued by high-recurrence rates and poor long-term outcomes which may be related to the absence of specific treatment for advanced and recurrent disease.
Keywords: Fibrolamellar hepatocellular carcinoma; Hepatocellular carcinoma; Liver cancer.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.Eur J Cancer. 2013 Aug;49(12):2698-704. doi: 10.1016/j.ejca.2013.04.012. Epub 2013 May 15. Eur J Cancer. 2013. PMID: 23683550
-
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection.Cancer. 2012 Oct 15;118(20):4981-90. doi: 10.1002/cncr.27520. Epub 2012 Mar 13. Cancer. 2012. PMID: 22415897
-
Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.World J Surg Oncol. 2020 May 12;18(1):93. doi: 10.1186/s12957-020-01855-2. World J Surg Oncol. 2020. PMID: 32397993 Free PMC article.
-
Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review.Liver Transpl Surg. 1999 Mar;5(2):91-5. doi: 10.1002/lt.500050201. Liver Transpl Surg. 1999. PMID: 10071346 Review.
-
Fibrolamellar hepatocellular carcinoma in children and adolescents.Cancer. 2003 Apr 15;97(8):2006-12. doi: 10.1002/cncr.11292. Cancer. 2003. PMID: 12673731 Review.
Cited by
-
A Case of a Boy With Undiagnosed Fibrolamellar Carcinoma Who Died Due to Severe Hemorrhage From Diaphragm.Cureus. 2024 Apr 30;16(4):e59355. doi: 10.7759/cureus.59355. eCollection 2024 Apr. Cureus. 2024. PMID: 38817535 Free PMC article.
-
Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001-2020.medRxiv [Preprint]. 2024 Apr 5:2024.03.25.24304564. doi: 10.1101/2024.03.25.24304564. medRxiv. 2024. PMID: 38633779 Free PMC article. Preprint.
-
Genomic Variations Between Fibrolamellar and Conventional Hepatocellular Carcinomas.Cureus. 2023 Dec 19;15(12):e50795. doi: 10.7759/cureus.50795. eCollection 2023 Dec. Cureus. 2023. PMID: 38116022 Free PMC article.
-
Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics.J Hepatocell Carcinoma. 2023 Nov 1;10:1923-1933. doi: 10.2147/JHC.S428741. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 37933267 Free PMC article.
References
-
- Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood.AMA J Dis Child. Feb 1956;91(2):168-86. 10.1001/archpedi.1956.02060020170015 - PubMed
-
- Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. Journal of the American College of Surgeons. Dec 2012;215(6):820-30. 10.1016/j.jamcollsurg.2012.08.001 - PubMed
-
- O'Neill AF, Church AJ, Perez-Atayde AR, Shaikh R, Marcus KJ, Vakili K. Fibrolamellar carcinoma: An entity all its own. Curr Probl Cancer. Aug 2021;45(4):100770. 10.1016/j.currproblcancer.2021.100770 - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous